Dr. Jonathan Wesley Riess, MD, MS

Dr. Riess practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Riess' NPI, 1619132461, was assigned on July 22, 2008. Dr. Riess graduated from Rutgers Robert Wood Johnson Medical School in 2006. Dr. Riess holds California license A103441.

Dr. Riess' primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Riess' primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Riess is also affiliated with Renown Regional Medical Center. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Riess to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Riess practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Riess' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Riess is board certified in medical oncology by the American Board of Internal Medicine. Dr. Riess is licensed in California.

Dmand AI lists chronic leukemia and lung cancer among the conditions Dr. Riess treats.

CMS data shows 617 Medicare services from Dr. Riess across 8 procedure codes in 2024, for 169 Medicare patients. Medicare paid $34,115 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 169 Medicare patients who saw Dr. Riess in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have cancer, and 66% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Riess' median patient age at 70, with 61% women.

In 2024, Dr. Riess wrote 565 Medicare Part D claims for 67 patients. 53% of them were for generic drugs. CMS names the drug for 393 of them, across 11 drugs with 11 or more claims each, at $3,318,782 in total drug cost. In 2023, CMS named 408 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Riess for performance year 2024, reported as part of a group. Dr. Riess accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Riess as offering telehealth.

Dmand AI links 125 papers to Dr. Riess, published from 2012 to 2025. 2018 was the busiest year, with 14. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Riess has published most often in Clin Lung Cancer. Dr. Riess' most frequent co-authors are David Raymond Gandara, MD, Heather Ann Wakelee, MD and Joel William Neal, MD, PhD.

Dmand AI links Dr. Riess to 11 clinical trials, 5 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 272 general payments to Dr. Riess from 37 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 85% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $24,029. It also lists 20 research payments totaling $26,244 from 2019 to 2025.

Dmand AI lists 1 award for Dr. Riess, most recently CMS Stage 1 EHR in 2014.

Dr. Riess graduated from Rutgers Robert Wood Johnson Medical School in 2006.

Dr. Riess is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.